Meeting with Olivér Várhelyi (Commissioner) and 29 other attendees

2 Oct 2025 · All pressing portfolio topics

Meeting with Vincenzo Matano (Cabinet of Executive Vice-President Raffaele Fitto) and 2 other interest representatives

17 Sept 2025 · Introductory Meeting on Coalizione VITA Activities

Meeting with Adam Jarubas (Member of the European Parliament, Committee chair)

21 Mar 2025 · Choroby rzadkie

Meeting with Eszter Lakos (Member of the European Parliament)

19 Mar 2025 · Biotechnology policy

Meeting with Nicolás González Casares (Member of the European Parliament) and Novavax

19 Mar 2025 · Health

Meeting with Ondřej Knotek (Member of the European Parliament)

9 Jan 2024 · Pharmaceutical package

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and 11 other interest representatives

18 Jul 2023 · Directive on Medicinal products for human use

Response to Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006

26 Jun 2023

Response to Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC

26 Jun 2023

Response to Report from the Commission to the EP and Council on the operation and performance of the Directive 2011/24/EU on the application of patient rights in cross-border healthcare foreseen under Article 17(1) and Article 20(1) & (2) of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011

1 Feb 2021

Response to Proposal for an EP and Council Regulation on orphan and paediatric medicinal products

7 Dec 2020

Response to Commission Communication on a Pharmaceutical Strategy- Ensuring sustainable innovation and the availability and affordability of medicines and medical technologies for citizens

2 Jul 2020

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis)

2 Jun 2016 · HTA